Percorten-V Desoxycorticosterone Pivalate Injection) Canine Endocrine Therapeutics: The Definitive Guide to Mineralocorticoid Pharmacology, Electrolyte Homeostasis, and Clinical Management
Managing canine primary hypoadrenocorticism (Addison’s Disease), severe electrolyte imbalances, profound hyponatremia, hyperkalemic cardiotoxicity, and life-threatening hypovolemic shock in canine patients requires a gold-standard, long-acting mineralocorticoid replacement therapy that restores normal renal electrolyte handling without inducing glucocorticoid excess. When dogs suffer from adrenal cortex atrophy, inadequate endogenous aldosterone production, dangerous sodium wasting, and severe potassium retention, targeted parenteral hormonal intervention is essential to replenish essential mineralocorticoids, normalize serum electrolyte ratios, and sustain normal blood pressure and vascular perfusion.
Left unmanaged, canine Addisonian crises lead to severe cardiac arrhythmias, profound bradycardia, vascular collapse, renal failure, and fatal cardiovascular shock.
Relying solely on acute fluid resuscitation or short-acting oral steroids frequently fails to maintain stable, long-term electrolyte homeostasis or prevent recurring crisis episodes in chronic hypoadrenocorticism.
To provide targeted, life-sustaining endocrine support backed by veterinary clinical standards, modern veterinary endocrinology relies on premier sustained-release mineralocorticoid injectables. Percorten-V ($25\ \text{mg/mL}$, $3.8\ \text{mL}$ Vial Format / Desoxycorticosterone Pivalate Injection) is a premier, professional-grade parenteral mineralocorticoid formulation formulated to deliver controlled, prolonged release of active desoxycorticosterone pivalate ($\text{DOCP}$), engineered to regulate sodium and potassium balance in dogs suffering from hypoadrenocorticism.
Endocrine Pharmacology & Electrolyte Regulation Kinetics
Percorten-V delivers a targeted biochemical mechanism engineered to restore renal electrolyte reabsorption and systemic fluid balance:
[Percorten-V 25 mg/mL Suspension Administered Subcutaneously Every 25-30 Days]
|
[Slow, Controlled Systemic Release of Desoxycorticosterone Pivalate]
|
[Binding to Mineralocorticoid Receptors in Distal Renal Tubules]
|
-------------------------------------------------
| |
[ENHANCEMENT OF SODIUM REABSORPTION] [ENHANCEMENT OF POTASSIUM EXCRETION]
(Retains Sodium and Chloride in Bloodstream) (Promotes Renal Potassium Elimination in Urine)
| |
v v
[RESTORATION OF FLUID VOLUME] [NORMALIZATION OF SODIUM-TO-POTASSIUM RATIO]
(Expands Intravascular Blood Volume) (Corrects Dangerous Hyperkalemia & Hyponatremia)
| |
v v
[Prevention of Addisonian Crises] [Stabilization of Cardiac Conduction]
(Maintains Normal Blood Pressure & Perfusion) (Eliminates Risk of Arrhythmias and Shock)
| |
=========================> <=====================
|
v
[Complete Endocrine Homeostasis and Electrolyte Balance]
|
[Sustained Normal Hydration, Stable Cardiac Function, & Peak Canine Vitality]
1. Mechanism of Action and Molecular Structure
Desoxycorticosterone Pivalate ($\text{DOCP}$) is a potent mineralocorticoid analog. It exerts its primary therapeutic effect by acting on the distal renal tubules of the kidneys, promoting the active reabsorption of sodium and chloride ions while stimulating the excretion of potassium and hydrogen ions. By restoring normal sodium and potassium balance (optimizing the $\text{Na:K}$ ratio), $\text{DOCP}$ expands extracellular fluid volume, stabilizes blood pressure, and reverses the metabolic abnormalities characteristic of Addison’s disease.
2. Pharmacokinetic Profile
Sustained Subcutaneous Release: Formulated as an oily microcrystalline suspension that dissolves slowly following subcutaneous injection, providing a steady, predictable release of active drug over a prolonged duration.
Extended Dosing Interval: Designed to maintain consistent therapeutic mineralocorticoid activity for approximately 25 to 30 days, minimizing the need for daily injections.
Primary Clinical Indications
Percorten-V $25\ \text{mg/mL}$ ($3.8\ \text{mL}$ Vial) is utilized across specialized canine veterinary clinical protocols for:
Treatment of Canine Primary Hypoadrenocorticism (Addison’s Disease): Long-term management and hormone replacement therapy for dogs suffering from inadequate endogenous mineralocorticoid secretion.
Electrolyte Stabilization: Correction and prevention of life-threatening hyperkalemia (elevated blood potassium) and hyponatremia (depleted blood sodium) associated with Addisonian states.
Recommended Administration and Dosing Protocols
To guarantee absolute precision, safe subcutaneous delivery, and individualized hormonal balance, Percorten-V must be administered strictly under veterinary supervision with regular electrolyte monitoring.
Dosing Reference Table
The table below outlines standard operational parameters for Percorten-V $25\ \text{mg/mL}$ ($3.8\ \text{mL}$ Vial):
| Parameter | Operational Specification |
| Vial Concentration | Sterile aqueous suspension containing $25\ \text{mg}$ of Desoxycorticosterone Pivalate per $1\ \text{mL}$ ($3.8\ \text{mL}$ total volume) |
| Initial Starting Dosage | $2.2\ \text{mg/kg}$ ($1.0\ \text{mg/lb}$) body weight administered subcutaneously every 25 days |
| Primary Administration Route | Subcutaneous ($\text{SC}$) injection |
| Target Species | Canine patients diagnosed with primary hypoadrenocorticism (Addison’s disease) |
Clinical Safety, Precautions, and Storage
Concurrent Glucocorticoid Requirement: Because Percorten-V provides strictly mineralocorticoid activity, dogs with Addison’s disease typically require concurrent daily oral glucocorticoid supplementation (such as prednisone or prednisolone) to replace missing cortisol.
Monitoring Required: Regular monitoring of serum sodium, potassium, and clinical signs (such as lethargy, vomiting, or polyuria) is mandatory during initial dose titration and long-term maintenance.
Storage Parameters: Store at controlled room temperature between 15°C and 30°C (59°F and 86°F). Protect from freezing and shake well before each use.
Frequently Asked Questions (FAQ)
What is the active ingredient in Percorten-V?
Each milliliter contains Desoxycorticosterone Pivalate ($\text{DOCP}$) at $25\ \text{mg/mL}$, a long-acting mineralocorticoid hormone replacement.
How is Percorten-V administered to dogs?
It is administered via subcutaneous ($\text{SC}$) injection, typically repeated every 25 to 30 days based on individual patient electrolyte monitoring.
Why do dogs with Addison’s disease need Percorten-V?
Dogs with Addison’s disease lack natural aldosterone, leading to dangerous sodium loss and potassium buildup. Percorten-V restores normal sodium-potassium balance, preventing fatal cardiac arrhythmias and shock.
Where can I buy genuine Percorten-V for Dogs online?
You can safely source authentic, pharmaceutical-grade Percorten®-V ($25\ \text{mg/mL}$, $3.8\ \text{mL}$ Vial) online through Equines Vet Care. We store all specialized veterinary endocrine preparations under rigorous climate-controlled conditions to guarantee absolute product freshness, safety, and full potency.
Secure Professional Sourcing from Equines Vet Care
At Equines Vet Care, we understand that managing canine Addison’s disease, maintaining endocrine stability, and ensuring precise hormonal therapy require uncompromising product purity and strict quality control. Every unit of Percorten-V ($25\ \text{mg/mL}$, $3.8\ \text{mL}$ Vial) is procured through authorized distribution networks, stored in our climate-controlled facility, and dispatched with precision.
Percorten-V (desoxycorticosterone pivalate) is a vital replacement therapy for dogs suffering from primary adrenocortical insufficiency, commonly known as Addison’s Disease. This condition, also referred to as hypoadrenocorticism, occurs when a dog’s adrenal glands fail to produce essential hormones, affecting metabolism, blood pressure, and stress response. Percorten-V, with its active ingredient desoxycorticosterone pivalate, mimics the natural hormone aldosterone, addressing the mineralocorticoid deficit and improving overall health.
Key Features:
Active Ingredient: 25 mg/ml desoxycorticosterone pivalate
Indication: Replacement therapy for mineralocorticoid deficiency in Addison’s Disease
Administration: Intramuscular (IM) injection
Dosage: Initial dose of 1 mg per pound of body weight every 25 days
Benefits of Percorten-V for Dogs:
Improves Quality of Life: Enhances the well-being of dogs with Addison’s Disease
Normalizes Electrolyte Levels: Regulates sodium absorption and potassium excretion
Increases Blood Volume: Expands extracellular fluid volume, improving cardiac output and preventing hypotensive shock
Veterinarian Recommended: Trusted by professionals for effective management of hypoadrenocorticism
How Percorten-V Works:
Addison’s Disease is characterized by the insufficient production of hormones from the adrenal glands. Percorten-V provides a synthetic replacement for the mineralocorticoids that are lacking, thereby improving electrolyte balance and fluid retention. This helps maintain stable blood pressure and overall health in affected dogs.
Important Considerations:
Not a Cure: Percorten-V manages symptoms but does not cure Addison’s Disease
Glucocorticoid Therapy Required: Additional daily glucocorticoids (e.g., prednisone) are necessary for comprehensive treatment
Lifelong Treatment: Ongoing therapy with Percorten-V and glucocorticoids is required for managing the condition
Administration and Dosage:
Injection: Administered intramuscularly (IM)
Initial Dose: 1 mg per pound of body weight every 25 days
Follow Instructions: Administer exactly as directed by your veterinarian
For managing Addison’s Disease in dogs, Percorten-V offers a crucial solution to address mineralocorticoid deficiency and enhance quality of life. Ensure consistent administration and follow veterinary instructions for optimal results,
Reviews
There are no reviews yet.